2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2065

Higher Urate Volume Measured By Dual Energy Computed Tomography Is Associated with Unfavourable Cardiovascular Risks in Patients with Gout
Abstract Number: 867

Highly Sensitive Cardiac Troponin-I in Peripheral Blood Predicts Cardiovascular Events in Patients with Rheumatoid Arthritis
Abstract Number: 241

Histological and Clinical Correlates of Ultrasound Measures of Joint Inflammation: Analysis of RA Tissue Obtained By Ultrasound Guided Biopsy in Phase 1 of the Accelerating Medicines Partnership RA Network
Abstract Number: 2709

Histone Deacetylase 1 (HDAC1): A Novel Therapeutic Target for Patients with Rheumatoid Arthritis
Abstract Number: 2416

Histopathological Change Caused By Biological Treatment in Rheumatoid Arthritis Synovial Tissue
Abstract Number: 2200

History of Walking for Exercise Is Not Associated with More Symptomatic Knee Osteoarthritis: Data from the Osteoarthritis Initiative
Abstract Number: 270

HIV Infection and Avascular Necrosis in the Antiretroviral Era
Abstract Number: 919

HLA Type Imputation in the Genome Research in African American Scleroderma Patients (GRASP) Cohort Reveals Strong Associations of African Ancestry MHC Class II Types with Scleroderma and Lack of Class I HLA Type Associations
Abstract Number: 2037

HLA-B27 Testing in Patients >= 45 Years of Age and Subsequent Diagnosis of Late Onset Spondyloarthritis
Abstract Number: 1580

HLA-B27/ Human β2-Microglobulin (β2m) Transgenic Drosophila Expresses Specific Cross-Vein Less (CVL) and Small-Eye Phenotypes Resulting from Disruption of the BMP/TGFβ Signaling Pathway
Abstract Number: 1013

HLA-Class II Associations with ANCA-Associated Vasculitis in the Japanese Population: Different Features from European Populations
Abstract Number: 2158

HLA-DRB1*04:03/*04:06 As the Genetic Susceptibility to Dermatomyositis Positive for Anti-Transcriptional Intermediary Factor 1-γ Antibody in Japanese Population
Abstract Number: 1670

HMGB1-TLR4 Axis in Patients with Neuropsychiatric Systemic Lupus Erythematosus
Abstract Number: 2643

HO-1 Expression in Monocytes Might Regulate Kidney Damage in Lupus Nephritis Patients
Abstract Number: 687

Homocysteine Levels Are Independently Associated with Damage Accrual in Systemic Lupus Erythematosus Patients (SLE)

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].